IPI 145
- Product Name
- IPI 145
- CAS No.
- 1201438-56-3
- Chemical Name
- IPI 145
- Synonyms
- Duvelisib;CS-680;IPI-14;IPI-145;IPI 145;Duensibu;IPI-145, >=98%;IPI-145 INK197;IPI 145 USP/EP/BP;IPI-145 (INK-1197)
- CBNumber
- CB32645143
- Molecular Formula
- C22H17ClN6O
- Formula Weight
- 416.86
- MOL File
- 1201438-56-3.mol
IPI 145 Property
- Melting point:
- 205-206o C
- Boiling point:
- 757.8±60.0 °C(Predicted)
- Density
- 1.474±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- Soluble in DMSO (up to at least 25 mg/ml)
- form
- White solid.
- pka
- 10.05±0.10(Predicted)
- color
- White
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
N-Bromosuccinimide Price
- Product number
- 16800
- Product name
- IPI-145
- Purity
- ≥98%
- Packaging
- 500μg
- Price
- $68
- Updated
- 2024/03/01
- Product number
- 16800
- Product name
- IPI-145
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $121
- Updated
- 2024/03/01
- Product number
- 16800
- Product name
- IPI-145
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $201
- Updated
- 2024/03/01
- Product number
- 16800
- Product name
- IPI-145
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $335
- Updated
- 2024/03/01
- Product number
- I739400
- Product name
- IPI145
- Packaging
- 50mg
- Price
- $225
- Updated
- 2021/12/16
IPI 145 Chemical Properties,Usage,Production
Description
Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor cross-linking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2?Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, and others.3,4?Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5?Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes
Uses
IPI 145 is an 1,2-dihydroisoquinolin-1(2H)-one derivative and has been developed as a modulator of PI3 kinase.
Definition
ChEBI: 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone is a member of isoquinolines.
brand name
Copiktra
General Description
Class: lipid kinase; Treatment: CLL, SLL, FL; Other name: INK1197, IPI145; Oral bioavailability = 42%; Elimination half-life = 4.7 h; Protein binding = 98%
Pharmacokinetics
The recommended dose of duvelisib is 25 mg twice daily, much lower than that of idelalisib (150 mg, bid). Duvelisib is rapidly absorbed, with a peak concentration after 1–2 h. Following the administration of 25 mg of duvelisib, the absolute bioavailability in healthy volunteers is 42%. It is eliminated with a short half-life of 4.7 h, thus requiring twice daily administration.
target
PI3Kγ/δ
IC 50
Metabolism
Duvelisib is
primarily metabolized by CYP3A4 to give a monooxidation product, IPI-656, which has no
pharmacologically relevant activity.
References
1) Winkler?et al.?(2013),?PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Response and Suppresses Activity in Autoimmune and Inflammatory Disease Models;?Chem. Biol.?20?1309 2) Dong?et al.?(2014),?IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells;?Blood?124?3583 3) Flinn?et al.?(2018),?Duvelisib, a novel dual inhibitor of PI3K-δ/γ, is clinically active in advances hematologic malignancies;?Blood?131?877 4) Faia?et al.?(2018),?The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib, shows preclinical synergy with multiple targeted therapies in hematologic malignancies;?PLoS One?13?e0200725 5) Davis?et al.?(2017),?Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ;?Cancer Res.?77?2607
IPI 145 Preparation Products And Raw materials
Raw materials
Preparation Products
IPI 145 Suppliers
- Tel
- --
- Fax
- --
- litianang@caremo.com.cn
- Country
- China
- ProdList
- 271
- Advantage
- 58
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- 010-82848833 400-666-7788
- Fax
- 86-10-82849933
- jkinfo@jkchemical.com
- Country
- China
- ProdList
- 94657
- Advantage
- 76
- Tel
- +86-21-20908456
- Fax
- 021-58180499
- sales@BioChemBest.com
- Country
- China
- ProdList
- 6005
- Advantage
- 61
- Tel
- +86 (531) 88811783
- Fax
- +86 (531) 55696010 QQ 1762738062
- sales@trio-pharmatech.com (International market)
- Country
- China
- ProdList
- 1856
- Advantage
- 62
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Country
- China
- ProdList
- 4727
- Advantage
- 58
- Tel
- 86-21-60936353
- Fax
- 86-21-60936352
- Country
- China
- ProdList
- 335
- Advantage
- 58
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Fax
- +86-27-87599188
- Country
- China
- ProdList
- 1493
- Advantage
- 55
- Tel
- 021-58950125
- Fax
- (86) 21-58955996
- info@chemexpress.com
- Country
- China
- ProdList
- 7552
- Advantage
- 61
- Tel
- 400-400-6206333 18521732826
- Fax
- 021-50323701
- market@aladdin-e.com
- Country
- China
- ProdList
- 25003
- Advantage
- 65
View Lastest Price from IPI 145 manufacturers
- Product
- Duvelisib (IPI-145; INK1197) 1201438-56-3
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-11
- Product
- Duvelisib (IPI-145; INK1197) 1201438-56-3
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-09
- Product
- IPI 145 1201438-56-3
- Price
- US $5.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 1ton
- Release date
- 2019-09-03